QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Clinical trial NCT05799820 · UNKNOWN
Trial details
- NCT number
- NCT05799820
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-29
- Primary completion
- 2024-03-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.